{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T08:57:23Z","timestamp":1776329843731,"version":"3.50.1"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T00:00:00Z","timestamp":1772668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"vor","delay-in-days":42,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Inova Schar Molecular Tumor Board Philanthropy funds"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precis. Onc."],"DOI":"10.1038\/s41698-026-01351-y","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T23:05:32Z","timestamp":1772751932000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pan-cancer multi-omic ERBB2-HER2 characterization using next-generation sequencing and quantitative proteomics"],"prefix":"10.1038","volume":"10","author":[{"given":"Allison L.","family":"Hunt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamie","family":"Randall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan D.","family":"Ogata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Whitney","family":"Swain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Savannah","family":"Melvin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meenakshi","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valerie","family":"Calvert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. Larry","family":"Maxwell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas W.","family":"Bateman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuel F.","family":"Petricoin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas P.","family":"Conrads","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy L.","family":"Cannon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,5]]},"reference":[{"key":"1351_CR1","doi-asserted-by":"crossref","unstructured":"Cheng, X. A comprehensive review of HER2 in cancer biology and therapeutics. Genes 15 (2024).","DOI":"10.20944\/preprints202406.0515.v1"},{"key":"1351_CR2","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/35052073","volume":"2","author":"Y Yarden","year":"2001","unstructured":"Yarden, Y. & Sliwkowski, M. X. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. 2, 127\u2013137 (2001).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"1351_CR3","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.molmed.2007.10.002","volume":"13","author":"NV Sergina","year":"2007","unstructured":"Sergina, N. V. & Moasser, M. M. The HER family and cancer: emerging molecular mechanisms and therapeutic targets. Trends Mol. Med. 13, 527\u2013534 (2007).","journal-title":"Trends Mol. Med."},{"key":"1351_CR4","doi-asserted-by":"publisher","first-page":"S459","DOI":"10.1016\/j.annonc.2023.09.1840","volume":"34","author":"BT Li","year":"2023","unstructured":"Li, B. T. et al. 654O Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with solid tumors harboring specific HER2-activating mutations (HER2m): Primary results from the international phase II DESTINY-PanTumor01 (DPT-01) study. Ann. Oncol. 34, S459\u2013S460 (2023).","journal-title":"Ann. Oncol."},{"key":"1351_CR5","doi-asserted-by":"publisher","first-page":"LBA3000","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA3000","volume":"41","author":"F Meric-Bernstam","year":"2023","unstructured":"Meric-Bernstam, F. et al. Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) interim results. J. Clin. Oncol. 41, LBA3000\u2013LBA3000 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1351_CR6","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1200\/JCO.19.02488","volume":"38","author":"P Tarantino","year":"2020","unstructured":"Tarantino, P. et al. HER2-Low Breast Cancer: Pathological and Clinical Landscape. J. Clin. Oncol. 38, 1951\u20131962 (2020).","journal-title":"J. Clin. Oncol."},{"key":"1351_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-020-00208-2","volume":"7","author":"F Schettini","year":"2021","unstructured":"Schettini, F. et al. Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. NPJ Breast Cancer 7, 1 (2021).","journal-title":"NPJ Breast Cancer"},{"key":"1351_CR8","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi, S. et al. Trastuzumab Deruxtecan in previously treated HER2-low advanced breast cancer. N. Engl. J. Med. 387, 9\u201320 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1351_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00696-6","volume":"8","author":"LE Johnston","year":"2024","unstructured":"Johnston, L. E. et al. Proteomics based selection achieves complete response to HER2 therapy in HER2 IHC 0 breast cancer. npj Precis. Oncol. 8, 203 (2024).","journal-title":"npj Precis. Oncol."},{"key":"1351_CR10","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s12014-024-09476-7","volume":"21","author":"J Randall","year":"2024","unstructured":"Randall, J. et al. Quantitative proteomic analysis of HER2 protein expression in PDAC tumors. Clin. Proteom. 21, 24 (2024).","journal-title":"Clin. Proteom."},{"key":"1351_CR11","doi-asserted-by":"publisher","first-page":"6426","DOI":"10.1158\/1078-0432.CCR-12-0452","volume":"18","author":"JD Wulfkuhle","year":"2012","unstructured":"Wulfkuhle, J. D. et al. Molecular analysis of HER2 signaling in human breast cancer by functional protein pathway activation mapping. Clin. Cancer Res 18, 6426\u20136435 (2012).","journal-title":"Clin. Cancer Res"},{"key":"1351_CR12","doi-asserted-by":"publisher","first-page":"3133","DOI":"10.1200\/JCO.2019.37.15_suppl.3133","volume":"37","author":"JD Wulfkuhle","year":"2019","unstructured":"Wulfkuhle, J. D. et al. HER family protein expression and activation predicts response to combination T-DM1\/pertuzumab in HER2+ patients in the I-SPY 2 TRIAL. J. Clin. Oncol. 37, 3133\u20133133 (2019).","journal-title":"J. Clin. Oncol."},{"key":"1351_CR13","doi-asserted-by":"crossref","unstructured":"Wulfkuhle, J. D. et al. Evaluation of the HER\/PI3K\/AKT family signaling network as a predictive biomarker of pathologic complete response for patients with breast cancer treated with Neratinib in the I-SPY 2 TRIAL. JCO Precis. Oncol. 1\u201320 (2018).","DOI":"10.1200\/PO.18.00024"},{"key":"1351_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-025-00868-y","volume":"9","author":"AL Hunt","year":"2025","unstructured":"Hunt, A. L. et al. Real-time functional proteomics enhances therapeutic targeting in precision oncology molecular tumor boards. NPJ Precis. Oncol. 9, 111 (2025).","journal-title":"NPJ Precis. Oncol."},{"key":"1351_CR15","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1038\/s41591-023-02478-2","volume":"29","author":"F Mosele","year":"2023","unstructured":"Mosele, F. et al. Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial. Nat. Med. 29, 2110\u20132120 (2023).","journal-title":"Nat. Med."},{"key":"1351_CR16","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1002\/1878-0261.13091","volume":"16","author":"M Pierobon","year":"2022","unstructured":"Pierobon, M. et al. Multi-omic molecular profiling guide\u2019s efficacious treatment selection in refractory metastatic breast cancer: a prospective phase II clinical trial. Mol. Oncol. 16, 104\u2013115 (2022).","journal-title":"Mol. Oncol."},{"key":"1351_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101312","volume":"4","author":"RI Gallagher","year":"2023","unstructured":"Gallagher, R. I. et al. Protein signaling and drug target activation signatures to guide therapy prioritization: Therapeutic resistance and sensitivity in the I-SPY 2 Trial. Cell Rep. Med. 4, 101312 (2023).","journal-title":"Cell Rep. Med."},{"key":"1351_CR18","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1200\/JCO.2025.43.16_suppl.1032","volume":"43","author":"P Tarantino","year":"2025","unstructured":"Tarantino, P. et al. Quantitative pre-treatment assessment of trastuzumab deruxtecan (T-DXd) antibody target (HER2) and payload target (topoisomerase 1, Topo1) to predict outcomes in metastatic breast cancer (MBC). J. Clin. Oncol. 43, 1032\u20131032 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1351_CR19","doi-asserted-by":"publisher","unstructured":"Schlam, I., Tarantino, P. & Tolaney, S. M. Overcoming Resistance to HER2-directed therapies in breast cancer. Cancers 14, https:\/\/doi.org\/10.3390\/cancers14163996 (2022).","DOI":"10.3390\/cancers14163996"},{"key":"1351_CR20","doi-asserted-by":"publisher","first-page":"3242","DOI":"10.1200\/JCO.2011.39.2779","volume":"30","author":"LJ Esserman","year":"2012","unstructured":"Esserman, L. J. et al. Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results From the I-SPY 1 TRIAL\u2014CALGB 150007\/150012, ACRIN 6657. J. Clin. Oncol. 30, 3242\u20133249 (2012).","journal-title":"J. Clin. Oncol."},{"key":"1351_CR21","doi-asserted-by":"publisher","first-page":"883","DOI":"10.15252\/msb.20167144","volume":"12","author":"F Edfors","year":"2016","unstructured":"Edfors, F. et al. Gene-specific correlation of RNA and protein levels in human cells and tissues. Mol. Syst. Biol. 12, 883 (2016).","journal-title":"Mol. Syst. Biol."},{"key":"1351_CR22","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1074\/mcp.M100019-MCP200","volume":"1","author":"TF \u00d8rntoft","year":"2002","unstructured":"\u00d8rntoft, T. F., Thykjaer, T., Waldman, F. M., Wolf, H. & Celis, J. E. Genome-wide study of gene copy numbers, transcripts, and protein levels in pairs of non-invasive and invasive human transitional cell carcinomas. Mol. Cell. Proteom. 1, 37\u201345 (2002).","journal-title":"Mol. Cell. Proteom."},{"key":"1351_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2003-4-9-117","volume":"4","author":"D Greenbaum","year":"2003","unstructured":"Greenbaum, D., Colangelo, C., Williams, K. & Gerstein, M. Comparing protein abundance and mRNA expression levels on a genomic scale. Genome Biol. 4, 117 (2003).","journal-title":"Genome Biol."},{"key":"1351_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2021.102757","volume":"24","author":"AL Hunt","year":"2021","unstructured":"Hunt, A. L. et al. Extensive three-dimensional intratumor proteomic heterogeneity revealed by multiregion sampling in high-grade serous ovarian tumor specimens. iScience 24, 102757 (2021).","journal-title":"iScience"},{"key":"1351_CR25","doi-asserted-by":"publisher","unstructured":"Burdett, N. L. et al. Multiomic analysis of homologous recombination-deficient end-stage high-grade serous ovarian cancer. Nat. Genet. https:\/\/doi.org\/10.1038\/s41588-023-01320-2 (2023).","DOI":"10.1038\/s41588-023-01320-2"},{"key":"1351_CR26","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s12014-024-09451-2","volume":"21","author":"AL Hunt","year":"2024","unstructured":"Hunt, A. L. et al. Mapping three-dimensional intratumor proteomic heterogeneity in uterine serous carcinoma by multiregion microsampling. Clin. Proteom. 21, 4 (2024).","journal-title":"Clin. Proteom."},{"key":"1351_CR27","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1074\/mcp.M400055-MCP200","volume":"3","author":"Q Tian","year":"2004","unstructured":"Tian, Q. et al. Integrated genomic and proteomic analyses of gene expression in mammalian cells. Mol. Cell. Proteom. 3, 960\u2013969 (2004).","journal-title":"Mol. Cell. Proteom."},{"key":"1351_CR28","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1074\/mcp.M200008-MCP200","volume":"1","author":"G Chen","year":"2002","unstructured":"Chen, G. et al. Discordant protein and mRNA expression in lung adenocarcinomas. Mol. Cell Proteom. 1, 304\u2013313 (2002).","journal-title":"Mol. Cell Proteom."},{"key":"1351_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00519-8","volume":"8","author":"NW Bateman","year":"2024","unstructured":"Bateman, N. W. et al. Proteogenomic analysis of enriched HGSOC tumor epithelium identifies prognostic signatures and therapeutic vulnerabilities. npj Precis. Oncol. 8, 68 (2024).","journal-title":"npj Precis. Oncol."},{"key":"1351_CR30","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.cels.2017.08.013","volume":"5","author":"E Gon\u00e7alves","year":"2017","unstructured":"Gon\u00e7alves, E. et al. Widespread post-transcriptional attenuation of genomic copy-number variation in cancer. Cell Syst. 5, 386\u2013398.e384 (2017).","journal-title":"Cell Syst."},{"key":"1351_CR31","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/s41416-019-0635-y","volume":"122","author":"FW Hunter","year":"2020","unstructured":"Hunter, F. W. et al. Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer. Br. J. Cancer 122, 603\u2013612 (2020).","journal-title":"Br. J. Cancer"},{"key":"1351_CR32","first-page":"22","volume":"7","author":"K Saleh","year":"2024","unstructured":"Saleh, K. et al. Mechanisms of action and resistance to anti-HER2 antibody-drug conjugates in breast cancer. Cancer Drug Resist. 7, 22 (2024).","journal-title":"Cancer Drug Resist."},{"key":"1351_CR33","first-page":"21","volume":"10","author":"M Luque-Cabal","year":"2016","unstructured":"Luque-Cabal, M., Garc\u00eda-Teijido, P., Fern\u00e1ndez-P\u00e9rez, Y., S\u00e1nchez-Lorenzo, L. & Palacio-V\u00e1zquez, I. Mechanisms behind the resistance to Trastuzumab in HER2-amplified breast cancer and strategies to overcome it. Clin. Med Insights Oncol. 10, 21\u201330 (2016).","journal-title":"Clin. Med Insights Oncol."},{"key":"1351_CR34","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.06907","volume":"4","author":"AM Unni","year":"2015","unstructured":"Unni, A. M., Lockwood, W. W., Zejnullahu, K., Lee-Lin, S. Q. & Varmus, H. Evidence that synthetic lethality underlies the mutual exclusivity of oncogenic KRAS and EGFR mutations in lung adenocarcinoma. Elife 4, e06907 (2015).","journal-title":"Elife"},{"key":"1351_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-62096-x","volume":"14","author":"SM Lee","year":"2024","unstructured":"Lee, S. M. & Oh, H. RAS\/RAF mutations and microsatellite instability status in primary colorectal cancers according to HER2 amplification. Sci. Rep. 14, 11432 (2024).","journal-title":"Sci. Rep."},{"key":"1351_CR36","doi-asserted-by":"publisher","first-page":"D980","DOI":"10.1093\/nar\/gkt1113","volume":"42","author":"MJ Landrum","year":"2014","unstructured":"Landrum, M. J. et al. ClinVar: public archive of relationships among sequence variation and human phenotype. Nucleic Acids Res. 42, D980\u2013D985 (2014).","journal-title":"Nucleic Acids Res."},{"key":"1351_CR37","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1093\/bioinformatics\/btl117","volume":"22","author":"R Suzuki","year":"2006","unstructured":"Suzuki, R. & Shimodaira, H. Pvclust: an R package for assessing the uncertainty in hierarchical clustering. Bioinformatics 22, 1540\u20131542 (2006).","journal-title":"Bioinformatics"},{"key":"1351_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26019-y","volume":"12","author":"AS Clark","year":"2021","unstructured":"Clark, A. S. et al. Neoadjuvant T-DM1\/pertuzumab and paclitaxel\/trastuzumab\/pertuzumab for HER2(+) breast cancer in the adaptively randomized I-SPY2 trial. Nat. Commun. 12, 6428 (2021).","journal-title":"Nat. Commun."},{"key":"1351_CR39","doi-asserted-by":"publisher","first-page":"670","DOI":"10.7326\/0003-4819-139-8-200310210-00011","volume":"139","author":"EM Balk","year":"2003","unstructured":"Balk, E. M. et al. Effects of Statins on nonlipid serum markers associated with cardiovascular disease. Ann. Intern. Med. 139, 670\u2013682 (2003).","journal-title":"Ann. Intern. Med."},{"key":"1351_CR40","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/nrg3185","volume":"13","author":"C Vogel","year":"2012","unstructured":"Vogel, C. & Marcotte, E. M. Insights into the regulation of protein abundance from proteomic and transcriptomic analyses. Nat. Rev. Genet. 13, 227\u2013232 (2012).","journal-title":"Nat. Rev. Genet."},{"key":"1351_CR41","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1039\/B908315D","volume":"5","author":"R de Sousa Abreu","year":"2009","unstructured":"de Sousa Abreu, R., Penalva, L. O., Marcotte, E. M. & Vogel, C. Global signatures of protein and mRNA expression levels. Mol. Biosyst. 5, 1512\u20131526 (2009).","journal-title":"Mol. Biosyst."},{"key":"1351_CR42","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41435-024-00275-6","volume":"25","author":"X Li","year":"2024","unstructured":"Li, X., Zhao, L., Li, W., Gao, P. & Zhang, N. HER2-targeting CAR-T cells show highly efficient anti-tumor activity against glioblastoma both in vitro and in vivo. Genes Immun. 25, 201\u2013208 (2024).","journal-title":"Genes Immun."},{"key":"1351_CR43","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1158\/1078-0432.CCR-09-1322","volume":"16","author":"N Ahmed","year":"2010","unstructured":"Ahmed, N. et al. HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors. Clin. Cancer Res 16, 474\u2013485 (2010).","journal-title":"Clin. Cancer Res"},{"key":"1351_CR44","doi-asserted-by":"publisher","unstructured":"Zhang, C. et al. ErbB2\/HER2-Specific NK cells for targeted therapy of Glioblastoma. J. Natl. Cancer Inst. 108, https:\/\/doi.org\/10.1093\/jnci\/djv375 (2015).","DOI":"10.1093\/jnci\/djv375"},{"key":"1351_CR45","doi-asserted-by":"publisher","first-page":"21","DOI":"10.37796\/2211-8039.1001","volume":"10","author":"M Ramezani","year":"2020","unstructured":"Ramezani, M., Siami, S., Rezaei, M., Khazaei, S. & Sadeghi, M. An immunohistochemical study of HER2 expression in primary brain tumors. Biomedicine 10, 21\u201327 (2020).","journal-title":"Biomedicine"},{"key":"1351_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-08150-7","volume":"21","author":"B Xu","year":"2021","unstructured":"Xu, B. et al. The expression and prognostic value of the epidermal growth factor receptor family in glioma. BMC Cancer 21, 451 (2021).","journal-title":"BMC Cancer"},{"key":"1351_CR47","doi-asserted-by":"crossref","unstructured":"Beaubier, N. et al. Clinical validation of the Tempus xT next-generation targeted oncology sequencing assay. Oncotarget 10 (2019).","DOI":"10.18632\/oncotarget.26797"},{"key":"1351_CR48","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1038\/s41587-019-0259-z","volume":"37","author":"N Beaubier","year":"2019","unstructured":"Beaubier, N. et al. Integrated genomic profiling expands clinical options for patients with cancer. Nat. Biotechnol. 37, 1351\u20131360 (2019).","journal-title":"Nat. Biotechnol."},{"key":"1351_CR49","unstructured":"Tempus A. I., I. Tempus xT Validation Summary. Tempus AI, Inc. Official Website. https:\/\/www.tempus.com\/resources\/document-library\/Tempus-xT_Validation (2024)."},{"key":"1351_CR50","doi-asserted-by":"publisher","unstructured":"Hunt, A. L. et al. Integration of multi-omic data in a molecular tumor board reveals EGFR-associated ALK-inhibitor resistance in a patient with inflammatory myofibroblastic cancer. Oncologist https:\/\/doi.org\/10.1093\/oncolo\/oyad129 (2023).","DOI":"10.1093\/oncolo\/oyad129"},{"key":"1351_CR51","doi-asserted-by":"crossref","unstructured":"Baldelli, E. et al. in Molecular Profiling: Methods and Protocols Vol. 1606 (ed Virginia Espina) 149\u2013169 (Springer New York, 2017).","DOI":"10.1007\/978-1-4939-6990-6_11"},{"key":"1351_CR52","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3","volume":"3","author":"WJ Youden","year":"1950","unstructured":"Youden, W. J. Index for rating diagnostic tests. Cancer 3, 32\u201335 (1950).","journal-title":"Cancer"},{"key":"1351_CR53","unstructured":"R Core Team _R: A Language and Environment for Statistical Computing_. R Foundation for Statistical Computing, Vienna, Austria. https:\/\/www.R-project.org\/ (2024)."},{"key":"1351_CR54","doi-asserted-by":"publisher","unstructured":"Wickham, H. Welcome to the Tidyverse. J. Open Source Softw. 4 https:\/\/doi.org\/10.21105\/joss.01686 (2019).","DOI":"10.21105\/joss.01686"},{"key":"1351_CR55","doi-asserted-by":"publisher","unstructured":"Pantano, L. et al. DEGreport: Report of DEG analysis. https:\/\/doi.org\/10.18129\/B9.bioc.DEGreport, R package version 1.44.0, https:\/\/bioconductor.org\/packages\/DEGreport, https:\/\/bioconductor.org\/packages\/release\/bioc\/html\/DEGreport.html (2025).","DOI":"10.18129\/B9.bioc.DEGreport"},{"key":"1351_CR56","unstructured":"Aragon T epitools: Epidemiology Tools. R package version 0.5-10.1, https:\/\/CRAN.R-project.org\/package=epitools (2020)."}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01351-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01351-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01351-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T08:03:14Z","timestamp":1776326594000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01351-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,5]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1351"],"URL":"https:\/\/doi.org\/10.1038\/s41698-026-01351-y","relation":{},"ISSN":["2397-768X"],"issn-type":[{"value":"2397-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,5]]},"assertion":[{"value":"10 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"T.P.C. is a Thermo Fisher Scientific, Inc. SAB member and receives research funding from AbbVie. E.F.P. receives research funding from Genentech, Pfizer, Mirati, Springworks Therapeutics, Deciphera, AbbVie, and is a co-inventor of the RPPA Technology described herein, and related HER2 biomarker patents, and receives royalties on the related license agreements.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"153"}}